ClinicalTrials.gg
RecruitingNCT05775042Updated Oct 15, 2024

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

A Phase 2 interventional study of CM338 in IgA Nephropathy, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 127 studies in Glomerulonephritis, IGA with a site in China — 57 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
61st of 109
70 · median 84
Started
2023
with 10 others
Phase 2
27 of 127
14 open now
Primary completion
2027-06
later than 34 of 72 live
Registered
60th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 61st largest by planned enrollment of the 109 interventional ones that give a count, is one of 11 that started in 2023, is one of 27 in phase 2, reaches primary completion later than 34 of the 72 other live ones, and was the 60th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

57 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.

Read the detailed description

In 1968, immunoglobulin A nephropathy (IgAN) was developed by French pathologist Dr. Jean Berger and his colleague Dr. Nicole Hinglais that what is described as glomerular "immunoglobulin A (IgA)-immune globule" - immune globule Protein G (IgG) intercapillary deposition" of kidney disease, the main pathological feature of which is on the glomerulus IgA deposition, usually accompanied by local cell proliferation and stromal dilation. Since there is not enough specificity and spirit Biomarkers of sensitivity, the only way to confirm the diagnosis is renal biopsy.

03

Conditions studied

  • IgA Nephropathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-75.
  • Understand the nature of the study and sign the Form voluntarily.
  • Take effective measures throughout the study period.

Exclusion criteria

Exclusion Criteria:

  • Used other drugs within 30 days before the first study administration.
  • With previous history of (HIV) infection.
  • Treponema pallidum antibody positive in screening period.
  • May have active Mycobacterium tuberculosis infection.
  • Major surgery is planned during the study.
  • Other reasons the investigator believes that the subject is not suitable to participate in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Group A

    CM338 will be injected subcutaneously.

    Biological: CM338

  • Experimental
    Group B

    CM338 will be injected subcutaneously.

    Biological: CM338

  • Experimental
    Group C

    CM338 will be injected subcutaneously.

    Biological: CM338

Interventions

  • BiologicalCM338

    CM338 injection

06

What researchers measure

Primary outcomes

  1. The incidence of adverse events of CM338 in subjects with immunoglobulin A nephropathy

    To evaluate the incidence of adverse events, including abnormalities of laboratory examination, physical examination, vital signs, 12-lead electrocardiogram (12-ECG) and others.

    Time frame: up to week 112

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jun 2027, 49 months after the start.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
Mar 20, 2023
StartActual
May 8, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05775042
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
May 8, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 15, 2024

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Jicheng Lv
principal investigator · Peking University First Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CM338

Start the discussion